Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?

Japanese Journal of Clinical Oncology

Volumn 38, Issue 6, 2008, Pages 445-450

  Kim, Hee Seung ^a   Park, Noh Hyun ^a   Chung, Hyun Hoon ^a   Kim, Jae Weon ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Carboplatin; Consolidation chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EPITHELIUM TUMOR; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LEUKOPENIA; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; CARCINOMA; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 46349089711     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn034     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Sugiyama T, Ushijima K, Kamura T. New regimens for the treatment of gynecologic cancers. Gan To Kagaku Ryoho 2000;27:375-81.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally rcsccted stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
4. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999;65:243-9.
5. Berck J. Berck & Novak's gynecology. In: Berek JS, Natarajan S, editors. Ovarian and Fallopian Tube Cancer, 14th edn. Philadelphia: Lippincott Williams & Wilkins 2007.
6. Sabbatini P, Spriggs DR. Consolidation for ovarian cancer in remission. J Clin Oncol 2006;24:537-9.
7. Markman M. Consolidation/maintenance chemotherapy for ovarian cancer. Curr Oncol Rep 2003;5:454-8.
8. Skinner EN, Boruta DM, Gehrig PA, Boggess JF, Fowler WC, Jr, Van Le L. Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: An extended follow-up. Gynecol Oncol 2005;98:59-62.
9. Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, et al. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005;96:132-5.
10. Nicoletto MO, Tumolo S, Falci C, Donach M, Visona E, Rosabian A, et al. A randomized study of epithelial ovarian cancer: Is chemotherapy useful after complete remission? Int J Med Sci 2004;1:116-25.
11. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst 2005;97:560-6.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumor. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
14. Arbuck S, Ivy S, Setser A. The revise common toxicity criteria: Version 2.0. CTEP website: http://ctep.info.nih.gov
15. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95:161-92.
16. Micha JP, Goldstein BH, Graham C, Rettenmaier MA, Brown JV, 3rd, Hu JC, et al. Improved survival with single-agent paclitaxel consolidation/ maintenance therapy in advanced ovarian carcinoma. Oncology 2006;71:49-53.
17. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-5.
18. DiSilvestro PA, Fisher M, Pearl ML, Buhl A, Chalas E, Valea FA. Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy. Gynecol Obstet Invest 2007;63:1-6.
19. Rocconi RP, Straughn JM, Jr, Leath CA, 3rd, Kilgore LC, Hub WK, Barnes MN, 3rd, et al. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist 2006;11:336-41.
20. Tournigand C, Louvet C, Molitor JL, Fritel X, Dehni N, Sezeur A, et al. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol 2003;91:341-5.
21. Tournigand C, Louvet C, Molitor JL, Dehni N, Lejeune V, Sezeur A, et al. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol 2001;83:198-204.
22. Salerno MG, Ferrandina G, Greggi S, Pierelli L, Menichella G, Leone G, et al. High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: Long-term results. Bone Marrow Transplant 2001;27:1017-25.
23. Debby A, Levy T, Hayat H, Brenner Y, Glezerman M, Menczer J. Whole-abdomen, single-dose consolidation radiotherapy in patients with pathologically confirmed complete remission of advanced ovarian epithelial carcinoma: A long-term survival analysis. Int J Gynecol Cancer 2004;14:794-8.
24. Pectasides D, Pectasides E. Maintenance or consolidation therapy in advanced ovarian cancer. Oncology 2006;70:315-24.
25. Dearnley DD, McMeekin DS. Consolidation therapy in ovarian cancer: Where do we stand? Curr Opin Obstet Gynecol 2006;18:3-7.
26. Lee SJ, Lee JW, Min JA, Park CS, Kim BG, Lee JH, et al. A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy. Int J Gynecol Cancer 2006:16:95-100.